VA-FLIR-SYSTEMS
8.10.2020 14:02:14 CEST | Business Wire | Press release
FLIR Systems, Inc. (NASDAQ: FLIR) today announced four new additions to its Exx-Series of advanced thermal imaging cameras: the E96, E86, E76 and E54. Compared to predecessor Exx-Series cameras, the new cameras offer enhanced thermal resolution for more vibrant, easy-to-read images and on-camera routing capability to improve field survey efficiency. The new Exx-Series cameras are designed to help professionals detect the early signs of building issues, identify hot spots, troubleshoot electrical and mechanical systems, and prevent problems before they cause damage that leads to expensive repairs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201008005252/en/
The E96, with a 640x480 resolution and eight-times digital zoom, is the most advanced Exx-Series thermal camera to date. It delivers improved measurement results over the greatest distance to target, so professionals can safely diagnose electrical faults or locate hidden anomalies at very high temperatures up to 1500 degrees Celsius (2732 degrees Fahrenheit), including in harsh industrial environments such as steel mills or kilns, to help keep the workplace running smoothly.
For the first time, FLIR Inspection Route is now offered as a standard feature on every Exx-Series camera and is complemented by the FLIR Thermal Studio Pro software with Route Creator plugin, sold separately as an annual subscription. The complete routing bundle enables professionals to create and export custom inspection and pre-planned routes, ideal for large or multi-location electrical or mechanical projects.
“The new Exx-Series advanced thermal imaging cameras enable building professionals, inspectors, engineers, researchers, and facility maintenance personnel to do more than ever before with a handheld thermal camera,” said Rickard Lindvall, General Manager, Solutions Business at FLIR. “With improved thermal resolution and on-camera routing capabilities, the Exx Series can help our customers make better, informed decisions to complete the job more efficiently and effectively.”
The E96, E86, and E76 include UltraMax® high-definition image enhancement technology and improved contrast with one-touch level and spanning functions to view greater image details. In addition, interchangeable AutoCal™ lenses offer complete coverage of near and distance targets, with the built-in laser distance meter ensuring the crisp focus needed for accurate temperature measurement.
The new Exx-Series cameras are available globally starting today through authorized dealers and FLIR.com. To learn more about FLIR Systems’ entire Exx-Series line, visit: www.flir.com/exx-series .
Through March 31, 2021, customers who purchase an Exx-Series camera will receive a free three-month Thermal Studio Pro and Route Creator trial bundle. The FLIR Thermal Studio Suite is also available separately through an annual subscription in Standard and Pro versions, while the Starter version is offered at no charge. To learn more about FLIR Thermal Studio Suite, visit www.flir.com/thermal-studio-suite .
About FLIR Systems, Inc .
Founded in 1978, FLIR Systems is a world-leading industrial technology company focused on intelligent sensing solutions for defense and industrial applications. FLIR Systems’ vision is to be “The World’s Sixth Sense," creating technologies to help professionals make more informed decisions that save lives and livelihoods. For more information, please visit www.flir.com and follow @flir .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005252/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom